SCHEMBL7717819

SCHEMBL7717819

C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)/C=C/[C@H](O)C4(C(=O)C5CC5)CC4)CC[C@@H]23)C[C@@H](O)C[C@@H]1O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 13/20 0.75
ADORA3 P0DMS8 3/20 0.73
SLC6A2 P23975 3/20 0.73
NR1I2 O75469 2/20 0.73
PGR P06401 2/20 0.73
SLC6A4 P31645 2/20 0.73
ADRA1A P35348 2/20 0.73
PTGS2 P35354 2/20 0.73
HTR1A P08908 1/20 0.73
CYP24A1 Q07973 2/20 0.62
AGTR1 P30556 2/20 0.61
MAPT P10636 2/20 0.59
ABCB11 O95342 1/20 0.59
GC P02774 1/20 0.59
RXRA P19793 1/20 0.59
CHRM3 P20309 1/20 0.59
CNR1 P21554 1/20 0.59
HTR2C P28335 1/20 0.59
MAPK1 P28482 1/20 0.59
OPRD1 P41143 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7715724 1.00 VDR (0.75) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL7714471 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL7718712 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL12749728 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL8529871 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL7716289 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL7716477 0.92 VDR (0.77) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL8584234 0.90 VDR (0.81) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL8189116 0.90 VDR (0.74) VDRADORA3SLC6A2NR1I2PGR
SCHEMBL7710877 0.90 VDR (0.74) VDRADORA3SLC6A2NR1I2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0832063-B1 VITAMIN D DERIVATIVES WITH C-25 SUBSTITUENTS, PROCESS FOR THEIR PREPARATION, INTERMEDIATE PRODUCTS AND THEIR USE IN PREPARING MEDICAMENTS SCHERING AG (DE) 2000-02-23 EP claimed
US-6376480-B1 TREATMENT OF IMMUNE SYSTEM DISORDERS, OSTEOPOROSIS, ALOPECIA SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-23 US disclosed